Introduction
============

Head and neck cancer (HNC) is the ninth most common malignancy worldwide and the third most common in developing counties with high mortality rates [@B1]. Greater than ninety percent of HNCs are derived from squamous epithelium. Treatment of HNCs is multidisciplinary. One of the main treatments is radiotherapy. Currently, the development of new technologies, such as intensity-modulated radiotherapy (IMRT) and concurrent chemoradiotherapy (CCRT), have resulted in improvements in the clinical outcome of patients. However, in the past decades, the 5-year survival rate of radical radiotherapy remained at approximately fifty percent. Unfortunately, local recurrence occurs in fifty percent of patients. In this era, tumor immunotherapy has received considerable attention in the treatment of cancer. Therefore, new synergistic targets for a combination of radiotherapy with immunotherapy are urgently required.

As one of the immune escape checkpoints, programmed cell death protein 1 (PD-1), has gained considerable attention to date. Seiwert, T. Y. et al. [@B2] established the basis of the application of pembrolizumab, a PD-1 antibody, in the recurrence and metastasis of refractory head and neck squamous cell carcinoma (HNSCC). Currently, pembrolizumab has been approved by the Food and Drug Administration (FDA) for patients with HNSCC who have progressed, relapsed or metastasized after chemotherapy based on platinum [@B3]. However, the response rate of single pembrolizumab treatment was only 18 percent [@B2]. In addition to mediating the effects of cytotoxic activity and cytostatic activity on cancer cells, radiotherapy also exhibits immunomodulatory effects [@B4], [@B5]. Therefore, a combination of radiotherapy and immunotherapy may improve the therapeutic response. An animal experiment demonstrated that the combination of radiation with PD-1 blockade improved local tumor control [@B6]. However, clinical evidence for PD-1/PD-L1 blockade combined with radiotherapy has not been reported. In addition, the relation of PD-L1/PD-1 expression and radiosensitivity has rarely been reported. One study recently demonstrated that high PD-L1 expression in head and neck cancer was associated with increased rates of response to radiotherapy, but the results failed to reach statistical significance [@B7]. Thus, this study aims to explore the correlation between the PD-1/PD-L1 expression and radiosensitivity in HNCs and provide a powerful theoretical basis for the clinical feasibility of anti-PD-1/PD-L1 in combination with radiotherapy.

An increasingly important risk factor for HNCs is human papilloma virus (HPV) infection. The percentage of HPV infection in HNCs is 57-72 percent. The highest incidence is noted in oropharyngeal cancer in Western countries, and HPV infection is noted in 25 percent of other oral cancers [@B8]. HPV-positive HNCs exhibit a better prognosis compared with HPV-negative HNCs. This suggests that the worse clinical outcomes of patients with HPV-negative status may be related to intrinsic radiosensitivity [@B9]. Previous research [@B2] has demonstrated that the rate of pembrolizumab efficacy was significantly increased in HPV-positive HNCs. Thus, this study intends to evaluate the correlation between PD-1/PD-L1 expression and HPV and discuss the potential targets of PD-1 and PD-L1 to regulate radiosensitivity. Furthermore, we sought to provide a new evaluation index for selecting cases that will benefit from combination treatment of radiotherapy and PD-1/PD-L1 immune therapy.

In the present study, we validated a 31-gene signature that is associated with radiosensitivity in the head and neck cancer population. We then first analyzed the relationship between basal PD-1/PD-L1 expression and clinical factors, including radiosensitivity and HPV/p16 status in a large cohort. Furthermore, we first examined the prognostic role of basal PD-1/PD-L1 expression in the context of radiosensitivity to propose a potential group that would most likely benefit from the combination of radiotherapy and immunotherapy.

Materials and Methods
=====================

Data sets
---------

Transcriptome profiling data and clinical data were obtained from the TCGA. We downloaded these data from UCSC Xena (<https://xenabrowser.net/datapages/>) using the categories of gene expression RNAseq (IlluminaHiSeq) and phenotype (phenotype). These transcriptome profiling data include gene-level transcription estimates reported as log2(x+1)-transformed RSEM normalized counts. We chose head and neck cancer with transcriptome profiling data available for cancer and normal tissue samples. The phenotype sample types were "Primary Tumor" and "solid normal tissue". A data set of normalized results representing gene expression was acquired. A total of 604 samples were collected in the data set, which was accessed during January 2018. These samples were matched with the accompanying data of clinical information. We excluded samples with no survival data (n=3), no transcriptome profiling data (n=8), and metastatic data (n=2). In total, 517 primary tumor samples and 74 solid normal tissue samples were included in the study. The total population (n=517) consisted of 289 patients (55.9%) who received radiotherapy, 158 patients (30.6%) without radiotherapy and 70 patients (13.5%) with unknown treatment. We employed CD274 mRNA expression level as a surrogate of PD-L1 and PDCD1 mRNA as a surrogate of PD-1. The HPV status was determined using an HPV in situ hybridization (ISH) test, and the p16 status was assessed using p16 staining. Survival data, such as recurrence-free survival (RFS) and overall survival (OS), were obtained from the records in TCGA data set.

The definition of radiosensitivity and clustering analysis
----------------------------------------------------------

The radiosensitivity of samples was predicted by a 31-gene signature [@B10]. The radiosensitivity genes were identified in NCI-60 cancer cells. Based on the correlations between the gene expression levels and the survival fraction at 2 Gy (SF2), the 31-gene signature was defined. In summary, 21 genes were upregulated and 10 genes were downregulated in radioresistant (RR) cells relative to radiosensitive (RS) cells (Table [S5](#SM0){ref-type="supplementary-material"}).

The K-mean clustering [@B11] was employed to cluster patients into two groups, with k=2, based on the gene expression level of the 31 genes. Clusters were identified as the radioresistant group (RR group) or the radiosensitive group (RS group) based on their prognosis when RT was performed.

Immunohistochemistry
--------------------

A total of 114 biopsy samples from patients with primary oropharyngeal cancer were collected at the First Hospital of China Medical University between 2005 and 2011. All the patients accepted radical radiotherapy. Using 4 μm-thick sections, immunohistochemistry was performed. The primary antibody was PD-L1 (mouse anti-human PD-L1 monoclonal, dilution 1:100, Abcam). The percentage of positive cells and staining intensity were estimated. Consistent with previous reports [@B12], staining in more than 5% of the tumor cells was considered positive. For detection of p16, the primary antibody was p16-INK4 (mouse anti-human p16 monoclonal, dilution 1:50, BD Pharmingen™). P16 expression was considered positive if nuclear and cytoplasmic staining in 20% or more of the tumor cells [@B13]. The method applied is described in detail in our previous study [@B14].

Statistical analysis
--------------------

Data distributions were tested using the Kolmogorov-Smirnov test. Parametric or nonparametric tests were employed according to the results. Propensity score matching (PSM) was used to balance the bias of RR and RS groups. The chi-square test and the McNemar\'s test were performed to contrast clinical and pathologic characteristics between RR and RS groups. PD-L1 and PD-1 expression was compared based on radiosensitivity and p16 status using unpaired t test and ANOVA for continues variables. Paired t test and unpaired t test were employed to investigate the gene expression difference between tumor and normal tissue. The rate of survival was analyzed among the three groups based on the following expression levels: 1) \< 25th percentile; 2) 25th to 75th percentile; and 3) ≥ 75th percentile. Gehan-Breslow-Wilcoxon tests were used to determine whether the time to event was significantly different between the highest (≥ 75th percentile) and lowest (\< 25th percentile) groups [@B15]. Based on results in univariate analyses, Cox proportional hazards regression models were established. Two-tailed P-values less than 0.05 were considered significant statistically. Statistical analyses were performed using IBM SPSS Statistics software version 22 and GraphPad Prism software 7.00.

Results
=======

Validation of gene signature related to radiosensitivity
--------------------------------------------------------

In previous studies, PD-L1 expression was significantly increased in tumor tissues compared with para-tumor tissues in different cancers [@B16], [@B17]. Similarly, in our present study, PD-L1 expression is upregulated in tumor tissue (unpaired t test, P=0.0363; paired t test, P=0.0584). In addition, no significant difference in PD-1 expression was observed between tumor and para-tumor tissue (Figure [S1](#SM0){ref-type="supplementary-material"}). Furthermore, PD-L1 expression was significantly positively correlated with PD-1 expression in 517 samples (Pearson Correlation Coefficient, 0.515; P\<0.0001, Figure [S2](#SM0){ref-type="supplementary-material"}).

Recent studies have assessed the role of PD-1/PD-L1 in patients with HNC, but the relationship between PD-1/PD-L1 and radiosensitivity remained unexplored. Herein, we divided all the patients (n=517) into two clusters with different radiosensitivities, cluster 1 (n=302, 58.41%) and cluster 2 (n=215, 41.59%), based on a gene signature related to radiosensitivity (Figure [1](#F1){ref-type="fig"}). In the context of radiotherapy, patients in the cluster 2 versus cluster 1 exhibited a prolonged overall survival (OS) (HR, 0.6089; 95% CI, 0.4045 to 0.9167; P=0.0026) and recurrence-free survival (RFS) (HR, 0.6647; 95% CI, 0.4155 to 1.063; P=0.0121) over a 200-month follow-up period. Thus, cluster 1 was identified to be RR group and cluster 2 was RS group. Without radiotherapy, no survival differences were observed between two clusters (Figure [1](#F1){ref-type="fig"}).

Clinicopathological characteristics based on radiosensitivity
-------------------------------------------------------------

The clinicopathological features of patients are presented in Table [1](#T1){ref-type="table"}. The median follow-up time was 34.75 months (0.07-210.97 months).

Between the RR and RS groups, the significantly different factors include HPV status (P\<0.0001), p16 status (P\<0.0001), EGFR amplification status (P=0.006), pathologic T (P\<0.0001), pathologic N (P\<0.0001), neoplasm histologic grade (P\<0.0001), lymphovascular invasion present (P=0.013), targeted molecular therapy (P=0.021), margin status (P=0.002), PD-L1 expression level (P\<0.0001), and PD-1 expression level (P\<0.0001). Similar to previous studies [@B7], [@B18], we found that patients positive for HPV/p16 were more abundant in the RS group compared with the RR group (P\<0.0001), whereas patients with EGFR amplification were more common in the RR group compared with the RS group (P=0.006). After PSM analysis, two groups had similar clinicopathologic features (Table [2](#T2){ref-type="table"}). And survival analysis still showed different OS (P = 0.0006) and RFS (p = 0.0235) between RR group and the RS group (Figure [1](#F1){ref-type="fig"}).

Factors correlated with PD-L1 and PD-1 expression: radiosensitivity and HPV/p16 status
--------------------------------------------------------------------------------------

Fiedler M et al recently reported that high PD-L1 expression promoted increased radiotherapy response rates without reaching statistical significance [@B7]. Similarly, significant differences in PD-L1 and PD-1 status were noted between the RR and RS groups (Table [2](#T2){ref-type="table"}). Given the relationship between PD-L1 and PD-1 expression and radiosensitivity, we next assessed factors associated with PD-L1 and PD-1 expression via variance analysis (Table [3](#T3){ref-type="table"}). In univariate analysis, pathologic stage (P=0.019) and radiosensitivity (P\<0.0001) were significant factors associated with PD-L1 expression, whereas p16 (P=0.0002), neoplasm histologic grade (P=0.001) and radiosensitivity (P\<0.0001) were significantly associated with PD-1 expression. In multivariate analysis, pathologic stage (P=0.0128) was a significant factor associated with PD-L1 expression, and p16 status (P=0.0332) was a significant factor associated with PD-1 expression. Before and after PSM analysis, PD-L1 and PD-1 expression levels are significantly increased in the RS group compared with the RR group (P\<0.0001) (Figure [2](#F2){ref-type="fig"}).

Given that HPV/p16 status is associated with radiosensitivity and directly associated with cancer immunogenicity. We then analyzed the impact of HPV and p16 on PD-L1 and PD-1 expression. Before and after PSM analysis, PD-1 expression is significantly increased in the HPV-positive group and p16-positive group (Figure [2](#F2){ref-type="fig"}). However, we failed to identify a significant relationship between PD-L1 expression and HPV/p16 status. For a more comprehensive study, we estimated the correlations between PD-L1 expression and p16 status using immunohistochemistry. Patient biopsy samples (n=114) were assessed for PD-L1 and p16 expression in tumor tissues (Figure [3](#F3){ref-type="fig"}). PD-L1 positive expression was identified in 37 cases (32.5%), and p16 positive expression was identified in 28 cases (24.6%). Positive p16 status was associated with positive PD-L1 expression (P=0.0224).

Survival analysis based on radiosensitivity and PD-L1 status
------------------------------------------------------------

In previous studies, PD-L1 was proven to be a prognostic marker in different cohorts, such as male, smokers and patients with P16 negative status [@B19], [@B20]. Thus, in our study, we estimated whether PD-1 and PD-L1 are prognostic markers in patients with different radiosensitivities. We aim to determine the characteristics of patients who could benefit from anti-PD-1/PD-L1 therapy combined with radiotherapy.

Survival analysis was employed for patients treated with radiotherapy (n=289) stratified by RS and RR groups. As shown in previous studies [@B21], [@B22], we found that a negative or close margin status, low pathologic stage and HPV/p16 positive status predicted for significantly superior outcome (Table [4](#T4){ref-type="table"}). In univariate analysis, PD-L1 high expression was associated with worse OS (HR, 2.196; 95% CI, 1.081-4.46; p = 0.0108) compared with PD-L1 low expression in the RR group. Interestingly, PD-L1 high expression predicted worse OS in the patients with both HPV/p16 negative status and radioresistant gene signature (HPV: HR, 2.334; 95% CI, 0.7828-6.961; P=0.0313; p16: HR, 2.486; 95% CI, 0.8559-7.219; P=0.0192) (Figure [4](#F4){ref-type="fig"}). No prognostic impact of PD-L1 expression was noted in the RS group. In contrast, high PD-1 expression was a significant factor in the overall radiotherapy group (n=289) and predicted better RFS (HR, 0.4892; 95% CI, 0.2357-1.015; P=0.023) (Figure [4](#F4){ref-type="fig"}). We employed a Cox hazard regression model that included factors that were significant in univariate analysis (Table [5](#T5){ref-type="table"}). Margin status, pathologic stage, PD-L1 expression and radiosensitivity status were confirmed as independent prognostic parameters for OS and RFS in different groups.

For a more comprehensive study, we also evaluated the prognostic impact of radiosensitivity stratified by PD-L1 (Table [S1](#SM0){ref-type="supplementary-material"}) and PD-1 expression level (Table [S2](#SM0){ref-type="supplementary-material"}). In univariate analysis, in the PD-L1 high group, the RS group exhibited prolonged overall survival time (HR, 0.4858; 95% CI, 0.2136-1.105; P=0.0189) and reduced risk of recurrence (HR, 0.4371; 95% CI, 0.1421-1.345; P=0.0231) (Figure [S3](#SM0){ref-type="supplementary-material"}). No effect on OS and RFS was noted in the PD-L1 low group and overall group. This survival difference in the PD-L1 high group further validated the negative prognostic value of PD-L1 in the RR group and suggested the potential to reverse radioresistance through anti-PD-L1 therapy. Significant factors in univariate analysis and radiosensitivity status were taken into account in the multivariable analysis (Table [S3](#SM0){ref-type="supplementary-material"}).

Discussion
==========

PD-1 is expressed on activated B cells, CD4 and CD8 T cells, dendritic cells, natural killer cells, APCs and monocytes. In contrast, PD-L1 is widely expressed on B cells, T cells, dendritic cells, mesenchymal stem cells, macrophages and a wide variety of non-hematopoietic cells. Of note, PD-L1 is also expressed on various tumor cells, causing a negative effect on antitumor immunity [@B23].

Radiation-induced DNA damage causes cell death. In addition to the direct action on tumor cells, radiation also plays a role in immunomodulation. Radiation produces immunogenicity via dendritic cells, which consume tumor peptides of dead tumor cells and recruit cytotoxic T lymphocytes (CTL) into the tumor microenvironment. To escape the immunologic responses of the host, PD-L1 was expressed by tumor cells and induced T cell apoptosis [@B24]. Thus, the predictive value of basal PD-1/PD-L1 expression is our target.

As shown in previous studies [@B24], [@B25], the gene signature related to radiosensitivity [@B10] was associated with OS in glioma and RFS in breast cancer. Of note, in our work, the RS group exhibited both better OS and RFS rates compared with the RR group when patients received radiotherapy. The differences were not significant for patients who were not treated with radiotherapy. Therefore, the gene signature is a predictive marker for head and neck cancer patients who received radiotherapy.

To define the factors that impact radiosensitivity, we analyzed patient and tumor characteristics in RS and RR groups. In our study, alleged favorable prognostic factors for HNC, such as HPV-positive and p16-positive status, were more prevalent in the RS group. One potential explanation for the result is the better response to radiation therapy in HPV-positive or p16-positive tumors. This finding is consistent with the increased radiosensitivity reported by other groups [@B7], [@B16]. A recent study [@B26] of 26 HNSCC cases using flow cytometry analysis demonstrated that PD-1-positive TIL was increased in HPV-positive patients. In our large population, we demonstrated that PD-1 expression levels are significantly increased in the HPV-positive group and p16-positive group. A recent study [@B11] suggested that high mutation load correlates with improved response to anti-PD1 immunotherapy. The difference in mutation burden between HPV-positive and HPV-negative tumors may lead to the difference in PD-L1 expression. Thus, we hypothesized that HPV-mediated PD-1 expression could increase radiosensitivity. This hypothesis should be investigated in further studies.

We summarized recent studies concerning PD-L1 and PD-1 in HNCs in Table [S4](#SM0){ref-type="supplementary-material"}. In published correlative studies [@B17], [@B21], high PD-L1 expression was associated with worse OS and an increased risk for nodal metastasis. Lin, Y. M. et al. [@B20] reported high PD-L1 expression as a risk factor for OS in males and smokers, which was consistent with us. Our results indicate that PD-L1 expression was a negative prognostic factor for head and neck cancer in patients expressing the radioresistant gene signature, but the underlying mechanism is unclear. We previously demonstrated that EGFR-mediated endoplasmic reticulum stress (ERS) induced radioresistance in oropharyngeal carcinoma [@B27], [@B28] and was confirmed in this study. Concha-Benavente, F. et al. [@B24] reported that PD-L1 expression was induced in an EGFR-dependent manner. Thus, this phenomenon could be explained by the fact that PD-L1 upregulation is caused by EGFR, which inhibits the activation of CD8-positive T cells and causes tumor immune escape [@B29]. In contrast, our results are not consistent with previous studies demonstrating an adverse prognostic effect of PD-L1 expression in several subgroups of HNCs, including laryngeal cancer, oropharynx cancer and HPV-negative tumors [@B19], [@B30]. Vassilakopoulou, M. et al. [@B30] suggested that partial antitumor immunity may explain the observed survival benefit. Furthermore, in their study, automated quantitative protein analysis (AQUA) was employed to measure PD-L1 protein levels. This technique differs from immunohistochemistry employed in the majority of studies. In addition, the number of cases should also be considered. We also observed a significant positive prognostic value of high PD-1 expression. Recent studies indicate that low PD-1 expression was associated with increased risk for local recurrence and reduced OS [@B7], [@B22], which were similar with our findings. Interestingly, Kansy, B. A. et al. [@B31] reported that cells with extremely high PD-1 expression indicated significantly worse disease-free survival and an increased risk for recurrence. These findings warrant further studies.

Some limitations should be taken into account. First, immunohistochemistry was frequently adopted to measure gene expression in previous studies. However, we employed mRNA expression level as a surrogate. Second, the threshold of PD-L1 expression to determine high or low expression was dependent on the researchers\' subjectivity. In this study, our classification was based on the 25th percentile and 75th percentile of transformed RSEM values of mRNA level. This method was adopted from previous reports [@B15], [@B32].

Our innovation in this research is the value of basal PD-1/PD-L1 expression in predicting the radiosensitivity and prognostic role in the context of radiosensitivity and HPV status. Previously, animal studies were used to investigate combination strategies using blockade of PD-L1 or PD-1 with radiation in different tumor types to overcome radioresistance [@B33], [@B34]. The changes in PD-L1 expression due to radiotherapy were the main targets of previous studies [@B35]. However, the basal and intrinsic PD-1 and PD-L1 expression before radiation may predict the response to radiation therapy and was rarely reported. Recently, Fiedler, M. et al. [@B7] suggested that basal PD-L1 expression indicated radiosensitivity but failed to reach statistical significance. Numerous factors could explain this finding, such as the number of cases, stages of cancer involved, and PD-1 and PD-L1 evaluation methods. In this study, we first demonstrate that high basal PD-1 and PD-L1 expressions are strongly related to radiosensitivity in head and neck cancer.

Unfortunately, patients with HPV-negative tumors still have a high risk of locoregional failure and low 3-year survival rates and require more efficacious treatments. In the past few decades, the 5-year survival rate of radical radiotherapy has remained low. Radioresistant patients require a combination treatment. However, the prognostic roles of PD-1 and PD-L1 are still controversial (Table [S4](#SM0){ref-type="supplementary-material"}). Our results first indicated that PD-L1 expression was a negative prognostic factor for head and neck cancer in HPV/p16-negative patients expressing the radioresistant gene signature. This result indicates that patients with the radioresistant gene signature and HPV/p16-negative status seem to benefit more from radiotherapy combined with anti-PD-1/PD-L1 therapy. These findings provide insight into radioresistant and HPV-negative tumor treatment, particularly with respect to clinical trials in the future.
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![Validation of radiosensitivity gene signature in HNCs. Before PSM analysis, OS curve (A) and RFS curve (C) indicated the prolonged survival of patients with radiotherapy in cluster 2. P=0.0026 and P=0.0121, respectively. OS curve (B) and RFS curve (D) indicated no correlation between clusters and survival in patients not treated with radiotherapy. P=0.4739 and P=0.8764, respectively. After PSM analysis, OS curve (E) and RFS curve (G) indicated the prolonged survival of patients with radiotherapy in cluster 2. P=0.0006 and P=0.0235, respectively. OS curve (F) and RFS curve (H) indicated no correlation between clusters and survival in patients not treated with radiotherapy. P=0.9054 and P=0.8793, respectively. P-values calculated using the Gehan-Breslow-Wilcoxon test. (I) Heatmap illustrating the relationship between the radiosensitivity gene signature of 31 genes and two groups before PSM analysis. Columns represent samples and radiosensitivity, and rows indicate genes expressed. Legend: blue, low expression; pink, high expression; green, cluster 1 group; pink, cluster 2 group.](jcav10p0937g001){#F1}

![Levels of PD-1 mRNA expression and PD-L1 mRNA expression in head and neck tumors before and after PSM analysis. PD-1 mRNA is upregulated in RS tumors (A), HPV-positive tumors (E) and P16-positive tumors (G) before PSM analysis. All P\<0.0001. After PSM analysis, PD-1 mRNA expression is also upregulated in RS tumors (B), HPV-positive tumors (F) and P16-positive tumors (H). P\<0.0001, P=0.0008 and P=0.0083, respectively. PD-L1 mRNA expression is upregulated in RS tumors before (C) and after (D) PSM analysis. P=0.0005 and P\<0.0001, respectively.](jcav10p0937g002){#F2}

![Representative immunohistochemical staining of p16 and PD-L1. P16-positive staining (A) demonstrates strong PD-L1 expression (B) on tumor cells. P16-negative staining (C) demonstrates negative PD-L1 expression (D) on tumor cells. Original magnification: ×400.](jcav10p0937g003){#F3}

![Kaplan-Meier curves analysis stratified by radiosensitivity. OS curve (A) and RFS curve (B) indicated worse prognosis of patients with high PD-L1 mRNA expression in the RR group compared with low PD-L1 mRNA expression. P=0.0108 and 0.0687, respectively. OS curves indicated worse prognosis of HPV (C) or p16 (D) negative status patients with high PD-L1 mRNA expression in the RR group compared with low PD-L1 mRNA expression. P=0.0313 and 0.0192, respectively. (E) OS curves indicated that the PD-1 mRNA level does not correlate with overall survival in all patients(n=289). P=0.1284. (F) RFS curves indicated that patients with low PD-1 mRNA levels recurred earlier than those with high PD-1 mRNA levels. P=0.0230. P values calculated by Gehan-Breslow-Wilcoxon test.](jcav10p0937g004){#F4}

###### 

Clinicopathological features according to radiosensitivity before PSM.

                                 RR(Cluster1)             RS(Cluster2)             Total          P-value
  ------------- ---------------- -------------- ------ -- -------------- ------ -- ------- ------ --------------
  Age           \<60             139            46.0      92             42.8      231     44.7   0.466^a^
                ≥60              163            54.0      123            57.2      286     55.3   
  Gender        Female           70             23.2      65             30.2      135     26.1   0.072
                Male             232            76.8      150            69.8      382     73.9   
  Alcohol       No               92             30.5      70             66.5      162     31.3   0.265
                Yes              201            66.6      143            32.6      344     66.5   
                unknown          9              3         2              0.9       11      2.1    
  Packs/year    \<40             203            67.2      148            68.8      351     67.9   0.698
                ≥40              99             32.8      67             31.2      166     32.1   
  HPV           Negative         35             11.6      30             14        65      12.6   **\<0.0001**
                Positive         3              1         18             8.4       21      4.1    
                unknown          264            87.4      167            77.7      431     83.4   
  P16           Negative         39             12.9      33             15.3      72      13.9   **\<0.0001**
                Positive         9              3         29             13.5      38      7.4    
                unknown          254            84.1      153            71.2      407     78.7   
  EGFR status   Unamplified      4              1.3       12             5.6       16      3.1    **0.006**
                Amplified        9              3         2              0.9       11      2.1    
                unknown          289            95.7      201            93.5      490     94.8   0.595
  Anatomic      Hypopharynx      6              2         4              1.9       10      1.9    
                Larynx           63             20.9      53             24.7      116     22.4   
                Oral             233            77.2      158            73.5      391     75.6   
  Grade         G1               43             14.2      19             8.8       62      12.0   **\<0.0001**
                G2               192            63.6      109            50.7      301     58.2   
                G3               58             19.2      67             31.2      125     24.2   
                G4               1              0.3       6              2.8       7       1.4    
                GX               6              2         12             5.6       18      3.5    
                unknown          2              0.7       2              0.9       4       0.8    
  Treatment     Surgery          60             19.9      40             18.6      100     19.3   0.723
                Radiation        24             7.9       12             5.6       36      7      
                Concurrent       22             7.3       21             9.8       43      8.3    
                Non-concurrent   4              1.3       3              1.4       7       1.4    
                unknown          192            63.6      139            64.7      331     64     
  Radiation     Yes              164            54.3      125            58.1      289     55.9   0.684
                No               96             31.8      62             28.8      158     30.6   
                unknown          42             13.9      28             13        70      13.5   
  Margin        Negative/Close   245            81.1      152            70.7      397     76.8   **0.002**
                Positive         34             11.3      25             11.6      59      11.4   
                unknown          23             7.6       38             17.7      61      11.8   
  CD274         High             48             15.9      81             37.7      129     25     **\<0.0001**
                Low              98             32.5      31             14.4      129     25     
                Medium           156            51.7      103            47.9      259     50.1   
  PDCD1         High             13             4.3       116            54        129     25     **\<0.0001**
                Low              124            41.1      5              2.3       129     25     
                medium           165            54.6      94             43.7      259     50.1   

a\. Chi-square test (and the Fisher\'s exact test when appropriate)

Abbreviations: Alcohol, alcohol history; Packs/year, packs/year smoked, HPV, HPV status assessed by ISH testing; P16, HPV status assessed by p16 testing; EGFR status, Epidermal growth factor receptor amplification status; Anatomic, anatomic neoplasm subdivision; Grade, neoplasm histologic grade; Concurrent, concurrent chemotherapy; Non-concurrent, chemotherapy not administered concurrently; RR, radioresistant group; RS, radiosensitive group.

###### 

Clinicopathological features according to radiosensitivity after PSM

                                 RR(Cluster1)             RS(Cluster2)             Total          P-value
  ------------- ---------------- -------------- ------ -- -------------- ------ -- ------- ------ --------------
  Age           \<60             89             45.9      80             41.2      169     43.6   0.431^a^
                ≥60              105            54.1      114            58.8      219     56.4   
  Gender        Female           47             24.2      60             30.9      107     27.6   0.154
                Male             147            75.8      134            69.1      281     72.4   
  Alcohol       No               59             30.4      62             32        121     31.2   0.570
                Yes              129            66.5      130            67        259     66.8   
                unknown          6              3.1       2              1         8       2.1    
  Packs/year    \<40             131            67.5      130            67        261     67.3   1.000
                ≥40              63             32.5      64             33        127     32.7   
  HPV           Negative         24             12.4      28             14.4      52      13.4   0.075
                Positive         3              1.5       12             6.2       15      3.9    
                unknown          167            86.1      154            79.4      321     82.7   
  P16           Negative         27             13.9      31             16        58      14.9   **0.018**
                Positive         6              3.1       19             9.8       25      6.4    
                unknown          161            83        144            74.2      305     78.6   
  EGFR status   Unamplified      4              1.3       11             5.7       15      3.9    0.067
                Amplified        7              3.6       1              0.5       8       2.1    
                unknown          183            94.3      182            93.8      365     94.1   
  Anatomic      Hypopharynx      3              1.5       4              2.1       7       1.8    0.670
                Larynx           39             20.1      49             25.3      88      22.7   
                Oral             152            78.4      141            72.7      293     75.5   
  Grade         G1               19             9.8       19             9.8       38      9.8    0.780
                G2               112            57.7      105            54.1      217     55.9   
                G3               54             27.8      60             30.9      114     29.4   
                G4               1              0.5       2              1         3       0.8    
                GX               6              3.1       7              3.6       13      3.4    
                unknown          2              1         1              0.5       3       0.8    
  Treatment     Surgery          41             21.1      38             19.6      79      20.4   0.596
                Radiation        14             7.2       12             6.2       26      6.7    
                Concurrent       20             10.3      15             7.7       35      9      
                Non-concurrent   2              1         1              0.5       3       0.8    
                unknown          117            60.3      128            66        245     63.1   
  Radiation     Yes              111            57.2      111            57.2      222     57.2   0.127
                No               62             32        60             30.9      122     31.4   
                unknown          21             10.8      23             11.9      44      11.3   
  Margin        Negative/Close   144            74.2      144            74.2      288     74.2   0.947
                Positive         28             14.4      25             12.9      53      13.7   
                unknown          22             11.3      38             12.9      47      12.1   
  T-stage       T1               15             7.7       22             11.3      37      9.5    0.087
                T2               51             26.3      55             28.4      106     27.3   
                T3               55             28.4      30             15.5      85      21.9   
                T4               51             26.3      59             30.4      110     28.4   
                TX               16             8.2       18             9.3       34      8.8    
                unknown          6              3.1       10             5.2       16      4.1    
  N-stage       N0               66             34        53             27.3      119     30.7   0.388
                N1               24             12.4      29             14.9      53      13.7   
                N2               62             32        62             32        124     32     
                N3               3              1.5       4              2.1       7       1.8    
                NX               32             16.5      35             18        67      17.3   
                unknown          7              3.6       11             5.7       18      4.6    
  Invasion      No               83             42.8      78             40.2      161     41.5   0.323
                Yes              55             28.4      45             23.2      100     25.8   
                unknown          56             28.9      71             36.6      127     32.7   
  Targeted      No               100            51.5      92             47.4      192     49.5   0.732
                Yes              59             30.4      63             32.5      122     31.4   
                unknown          35             18        39             20.1      74      19.1   
  CD274         High             32             16.5      65             33.5      97      25     **\<0.0001**
                Low              63             32.5      34             17.5      97      25     
                Medium           99             51        95             49        194     50     
  PDCD1         High             8              4.1       89             45.9      97      25     **\<0.0001**
                Low              89             45.9      8              4.1       97      25     
                medium           97             50        94             50        194     50     

a\. McNemar\'s Test (and the Bowker\'s Test when appropriate)

Abbreviations: Alcohol, alcohol history; Packs/year, packs/year smoked, HPV, HPV status assessed by ISH testing; P16, HPV status assessed by p16 testing; EGFR status, Epidermal growth factor receptor amplification status; Anatomic, anatomic neoplasm subdivision; Grade, neoplasm histologic grade; Concurrent, concurrent chemotherapy; Non-concurrent, chemotherapy not administered concurrently; Invasion, lymphovascular invasion present; Targeted, targeted molecular therapy; RR, radioresistant group; RS, radiosensitive group.

###### 

Univariate and multivariate variance analysis for PD-L1 and PD-1 expression.

                                   PD-L1                                              PD-1                              
  ------------------ ------------- ------------ -------------- ------- -------------- ------------ ------------ ------- --------------
  Variables                        Mean (SD)    p-value        F       p-value        Mean (SD)    p-value      F       p-value
  Age                \<60          6.20(1.55)   0.054                                 5.24(1.76)   0.164                
                     \>=60         6.48(1.69)                                         5.45(1.55)                        
  P16                Negative      6.55(1.54)   0.860                                 5.30(1.64)   **0.0002**   4.66    **0.033**
                     Positive      6.45(1.66)                                         6.62(1.85)                        
  Stage              I             7.17(1.68)   **0.019**      3.64    **0.013**      5.70(1.34)   0.407                
                     II            6.67(1.55)                                         5.42(1.83)                        
                     III           6.34(1.82)                                         5.29(1.61)                        
                     IV            6.21(1.54)                                         5.20(1.62)                        
  EGFR               Unamplified   6.50(1.50)   0.680                                 5.74(1.70)   0.211                
                     Amplified     6.95(1.92)                                         4.85(1.87)                        
  Grade              GX            6.69(1,23)   0.723                                 6.07(2.15)   **0.001**            
                     G1            6.53(1.67)                                         5.27(1.58)                        
                     G2            6.28(1.58)                                         5.14(1.55)                        
                     G3            6.40(1.75)                                         5.74(1.70)                        
                     G4            6.41(1.30)                                         6.53(1.57)                        
  Radiosensitivity   RR            4.44(1.30)   **\<0.0001**   32.35   **\<0.0001**   6.01(1.58)   **0.0001**   96.04   **\<0.0001**
                     RS            6.64(1.15)                                         6.85(1.62)                        

Abbreviations: Grade, neoplasm histologic grade; EGFR, Epidermal growth factor receptor amplification status; RR, radioresistant group; RS, radiosensitive group.

###### 

Univariate analysis for overall survival (OS) and recurrence-free survival (RFS)

                     OS                                                                                             RFS                                                                           
  ------------------ ------ ----------- ----------- ------ ------------ ----------- ------- ----------- ----------- ------ ----------- ----------- ------ ------------ ------- ------ ----------- -----------
  Age                                                                                                                                                                                             
  \<60               1                              1                               1                               1                              1                                              
  \>=60              1.05   0.64-1.72   0.860^a^    1.43   0.69-2.97    0.303       1.22    0.81-1.82   0.652       1.40   0.77-2.52   0.308       1.25   0.57-2.72    0.632   1.42   0.89-2.28   0.185
  Stage                                                                                                                                                                                           
  I to III           1                              1                               1                               1                              1                           1                  
  IV                 2.20   1.23-3.93   **0.014**   1.67   0.67-4.14    0.208       2.021   1.24-3.29   **0.006**   2.20   1.13-4.31   **0.009**   1.64   0.65-4.15    0.451   1.99   1.15-3.42   **0.01**
  HPV                                                                                                                                                                                             
  Positive           1                              1                                                               1                              1                           1                  
  Negative           2.87   0.14-60.2   0.505       2.22   0.38-12.95   0.147       2.85    0.90-9.04   **0.03**    2.9    0.07-121    0.583       0.29   0.046-1.88   0.625   0.78   0.19-3.25   0.538
  P16                                                                                                                                                                                             
  Positive           1                              1                               1                               1                                                          1                  
  Negative           1.68   0.33-8.45   0.579       5.82   1.08-31.33   **0.040**   3.53    1.28-9.78   **0.020**   3.40   0.35-32.9   0.297       0.88   0.18-4.15    0.63    1.58   0.48-5.23   0.155
  Margin                                                                                                                                                                                          
  Positive           1                              1                               1                               1                              1                           1                  
  Negative/Close     0.26   0.11-0.61   **0.012**   0.51   0.17-1.51    0.252       0.37    0.19-0.71   **0.009**   0.64   0.23-1.74   0.50        0.28   0.09-0.90    0.067   0.45   0.21-0.96   0.124
  PD-L1                                                                                                                                                                                           
  Low                1                              1                               1                               1                              1                           1                  
  High               2.20   1.08-4.46   **0.011**   1.07   0.40-2.88    0.929       1.51    0.82-2.76   0.134       1.67   0.76-3.69   0.069       0.59   0.19-1.82    0.361   0.78   0.39-1.56   0.650
  PD-1                                                                                                                                                                                            
  Low                1                              1                               1                               1                              1                           1                  
  High               1.05   0.49-2.24   0.440       1.29   0.47-3.58    0.990       0.68    0.38-1.21   0.128       1.12   0.49-2.60   0.417       0.37   0.10-1.37    0.248   0.9    0.24-1.02   **0.023**
  Radiosensitivity                                                                                                                                                                                
  RR                                                                                1                                                                                          1                  
  RS                                                                                0.61    0.40-0.92   **0.003**                                                              0.66   0.42-1.06   **0.012**

a\. Gehan-Breslow-Wilcoxon tests were used to determine whether the time to event significantly differed between the high expression group (≥ 75%) and low expression group (\< 25%) of PD-L1 and PD-1

Abbreviations: HPV, HPV status assessed by ISH testing; P16, HPV status assessed by p16 testing; RR, radioresistant group; RS, radiosensitive group.

###### 

Cox hazard regression models for overall survival (OS) and recurrence-free survival (RFS)

                                                     OS                                 RFS                
  ------------------ ------------------------------- ------ ------------ ----------- -- ------ ----------- -----------
  RR                                                                                                       
  Stage              I to IV (Incremental)           2.22   1.30-3.80    **0.004**      2.13   1.15-3.93   **0.016**
  Margin             Positive (vs. Negative/close)   2.72   1.42-5.21    **0.003**                         
  PD-L1              High (vs. Low)                  1.33   1.07-1.66    **0.010**      1.23   0.98-1.54   0.077
  RS                                                                                                       
  P16                Positive (vs. Negative)         0.02   0.00-18.98   0.261                             
  Overall                                                                                                  
  Stage              I to IV (Incremental)           1.80   1.19-2.72    **0.005**      1.63   1.05-2.51   **0.029**
  Margin             Positive (vs. Negative/close)   2.27   1.33-3.87    **0.003**                         
  PD-1               High (vs. Low)                                                     0.97   0.78-1.21   0.795
  Radiosensitivity   RR (vs. RS)                     1.76   1.09-2.85    **0.021**      1.43   0.70-2.91   0.330

Abbreviations: HPV, HPV status assessed by ISH testing; P16, HPV status assessed by p16 testing; RR, radioresistant group; RS, radiosensitive group.
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